Healthcare Investment Access (HIA) Programme
25 November 2025 - 26 March 2026
Seminar
HIA is a high-impact programme designed to elevate Nordic healthcare companies onto the global stage, with a strong emphasis on unlocking opportunities in the US capital markets.
Programme elements
The application process has been completed and the new cohort selected.
If you still wish to enquire about participation or have any questions, please contact the team members below. We will do our best to assist where possible.
Sharpen your pitch, elevate your presence and step into the spotlight
HIA is a high-impact programme designed to elevate Nordic healthcare companies onto the global stage, with a strong emphasis on unlocking opportunities in the US capital markets.
Programme highlights
- Connect directly with leading international investors, venture funds and strategic partners.
- Gain expert guidance on how to position your company for global capital engagement, with tailored insights into investor expectations outside the Nordic region.
- Initial 360° review and mentoring: Comprehensive, multidisciplinary evaluations covering clinical, commercial, regulatory and financing dimensions. These reviews identify blind spots, align strategic priorities and sharpen investor readiness. They are followed by two hours of mentoring with seasoned operators and investors, focusing on narrative development, milestone planning and market-entry strategies to elevate professionalism and execution.
- Learn how to craft compelling pitches and sharpen your messaging for US and European audiences.
- Maximixe visibility through curated investor interactions and spotlight appearances at premier events including the DNB Carnegie Nordic Healthcare Conference in Oslo, a strategically curated European Healthcare Investor Forum in Zurich, and the Nordic-American Healthcare Conference in NY.
- Selected companies will be eligible for a stipend to help assist with travel and external advisory needs.
Who should apply
- Nordic healthcare companies led by a CEO or senior executive
- Teams with at least a Minimum Viable Product (MVP) ready for clinical feedback
- Companies with no current US market presence, but a clear ambition to scale internationally
- Ventures with a strong value proposition and readiness to engage global stakeholders
Programme timeline
- 3 November 2025: Application deadline
- November 2025: Launch and pitch event in Oslo at the DNB Carnegie Nordic Healthcare Conference
- December 2025–March 2026: Individual investor readiness workshops, training and positioning sessions
- Feb 2026 (tbd): European Healthcare Investor Forum in Zurich
- 23–26 March 2026 : Market visit to New York, including pitch events and stakeholder meetings
Practical information
Important conditions
Companies must adhere to standards for responsible business conduct, including Environmental, Social, and Governance (ESG) criteria.
Participants are expected to operate in accordance with the UN Guiding Principles on Business and Human Rights and the OECD Guidelines for Multinational Enterprises on Responsible Business Conduct. This entails conducting business responsibly, respecting human rights, ensuring decent working conditions, safeguarding environmental considerations, and actively preventing corruption.
Companies must carry out their own due diligence assessments (risk assessments) to identify, prevent, and mitigate potential adverse impacts.